ClinicalTrials.gg
RecruitingNCT07348601Updated Oct 21, 2026

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

A Phase 2 interventional study of CSTI-500 in Prader-Willi Syndrome, sponsored by ConSynance Therapeutics. Recruiting at 1 site in United States. Open to participants aged 13 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by ConSynance Therapeutics · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
13 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Planned enrollment
40th of 58
12 · median 23
Started
2026
the only one that year
Phase 2
17 of 69
1 open now
Primary completion
2027-06
later than 8 of 13 live
Registered
67th of 69
by date
Lead sponsor
2 of 69
ConSynance Therapeutics

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 40th largest by planned enrollment of the 58 interventional ones that give a count, is the only one that started in 2026, is one of 17 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 67th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 13 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • PWS
  • Prader-Willi Syndrome
  • CSTI-500
04

Who can participate

Ages eligible
13 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Generally healthy male and female individuals between the ages of 13 and 50, inclusive
  2. Documented medical record history of PWS confirmed by genetic testing and PWS Nutritional Phase 3
  3. CGI-S score ≥4 at Screening and Baseline (behavioral)
  4. Screening HQ CT total scores ≥ 13
  5. Participants must not be taking SSRI, SNRI, DNRI (bupropion), tricyclic antidepressants, stimulants, antipsychotic medications, and MAO inhibitors within 30 days of screening and willing to not start taking these medications while on the study. Fluoxetine is exclusionary unless treatment has been discontinued >6 months prior to Screening.
  6. Caregiver/parent must agree to bring the subject to the site for the visits, remain with the subject during visit times when allowed and respond to any questions.
  7. Caregiver/parent is willing to provide and agrees to adhere to required study procedures including telemedicine visits, visit duration requirements, and offer consistent care.
  8. Caregivers must agree to complete all study required assessments.
  9. Participants who cannot consent for themselves and are able will provide assent.
  10. Female participants must not be pregnant or lactating. Nonpregnancy will be confirmed for all females by a urine pregnancy test conducted at Screening and at the Baseline Visit prior to enrollment into the study. If of , the subject/caregiver agrees to the use of one of the accepted regimens from Screening to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:

    1. Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
    2. Intrauterine device (with or without hormones)
    3. OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication.
    4. The investigator can use their judgement and familiarity with the participant's preferred and usual lifestyle to understand which form of birth control would be the best and also to determine if abstinence is an option that would achieve 100% effectiveness.
  11. If the female is of non-childbearing potential -surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is (at least 1 year without menses) as confirmed by follicle-stimulating hormone (FSH) levels of ≥ 40 mIU/mL. No contraceptive use is required.
  12. Unless, sterile, a male study subject/caregiver must agree to use a double barrier method (e.g., condom and spermicide).
  13. For adults, supine systolic blood pressure must be ≤140 mmHg and ≥100 mmHg; diastolic blood pressure must be ≤80 mmHg and ≥60 mmHg at Screening. Heart rate must be ≥50 bpm and ≤100 bpm. Heart rate increase on standing must be within acceptable range (see exclusion criterion 10).

    For adolescents, a systolic and diastolic BP that is between the 5th and 90th percentile for age and sex.

    a. Two repeat measurements within 10 minutes of the first reading are permitted at the discretion of the Investigator. If this option is used, the last obtained reading will be used for determination of eligibility. Averages will not be used.

  14. All concomitant medications including blood pressure medications and type 2 diabetic medications must be stable for ≥3 months prior to screening (≤10% change) and there must be no medication changes (dose change, initiation, discontinuation) intentionally planned during the study. Supplements and vitamins are not considered concomitant medications for eligibility purposes.
  15. Stated willingness to comply with all study procedures including visits, restrictions, and availability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Participation in any clinical study with an drug/device within 3 months prior to screening or during the study
  2. PWS diagnosis of UPD (maternal uniparental disomy).
  3. Current use of DCCR or if used previously, must be off at least 4 weeks before screening.
  4. Recent use (within 3 months) of weight loss agents including prescription, herbal medications, and weight loss supplements. Ozempic, for diabetes, would be exclusionary due to its effect on weight loss.
  5. History of bariatric surgery or major surgery within 6 months of screening or planned during the study.
  6. Any in the 2 years prior to screening (excluding basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
  7. Current liver, pulmonary, cardiac, or GI disease that would be expected to adversely affect study participation. Stable disease, e.g., asthma or controlled hypertension is not excluded. Liver disease or liver injury as indicated by abnormal liver function tests, , AST, alkaline phosphatase, or serum (≥3X for any of these tests).

    a. Participants with impaired liver function ( Scores A, B, C)

  8. Unexplained history or presence of combination of unexplained symptoms e.g., dizziness, syncope, fatigue, palpitations/tachycardia, headaches, or exercise intolerance.
  9. Prohibited Medications include SSRI, SNRI, DNRI (bupropion), tricyclic antidepressants, stimulants, antipsychotics, MAO inhibitors, fluoxetine, mood stabilizers, and GLP-1 agonists
  10. Presence of postural orthostatic tachycardia syndrome (POTS) for any reason, defined as:

    1. For participants aged 19 or older, sustained heart rate increase of >30 bpm or an increase to 120 bpm or greater within 3 minutes of standing.
    2. For participants aged 13-19, a sustained heart rate increase of >40 bpm or an increase to 120 bpm or greater within 3 minutes of standing.
    3. Associated with related symptoms that are worse with upright posture and that improve with recumbence.
  11. A abnormal finding on 12-lead (ECG) at Screening. Note corrected according to Fridericia's formula (QTcF) interval of ≥450 msec will be exclusionary [QTc = QT/(RR\^0.33)]. The ECG may be repeated once for confirmatory purposes if initial values obtained exceed the limits specified.
  12. Any clinically significant cardiac arrhythmia (e.g., atrial fibrillation, Adams-Stokes's disease, Wolff-Parkinson-White syndrome, atrioventricular block 2nd or 3rd degree).
  13. Heart failure classified per the (NYHA) as level II or greater.
  14. Myocardial infarction, stroke, or confirmed within the last 5 years.
  15. Estimated (eGFR) ≤ 90 mL/min/1.73m² for ages 13 to \<18 years of age. For adults ≥18 years of age, body-surface area corrected eGFR and exclusion with eGFR \<90 mL/min.
  16. Uncontrolled Type 2 diabetes as defined by ≥ 9% at Screening.
  17. Insulin-dependent Type 1 diabetes.
  18. Positive screen for surface antigen (HBsAg), virus (HCV) antibodies with detected circulating ribonucleic acid (RNA), or 1 and 2 antibodies.
  19. Uncontrolled thyroid disease.
  20. Known to any component of investigational product.
  21. History or active psychotic symptoms, or medical conditions which the investigator believes will interfere significantly with study compliance. Participants with a history of other severe psychiatric disorders, e.g., schizophrenia, major depressive disorder, bipolar disorder, or other disorders.
  22. History of any suicidal behavior.
  23. Known alcohol or substance abuse.
  24. Moderate to strong inhibitors/inducers of CYP2D6, and CYP2C9, including grapefruit juice. Substrates of CYP1A2 and CYP2B6.
  25. Any other medical, physical, or personal issues which, in the opinion of the investigator, would interfere with the subject's ability to complete the trial per protocol.
  26. Inability to swallow the oral capsules whole with water.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CSTI-500 (Open-label) Low Target Exposure

    Drug: CSTI-500

  • Experimental
    CSTI-500 (Open-Label) Medium Target Exposure

    Drug: CSTI-500

  • Experimental
    CSTI-500 (Open-label) High Target Exposure

    Drug: CSTI-500

Interventions

  • DrugCSTI-500

    CSTI-500 given orally in an open-label, dose-escalation design with individualized dosing.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Number of participants with TEAEs, defined as an adverse event (AE) that is new or worsened in severity after the dose of study drug (coded using MedDRA).

    Time frame: 14 weeks

  2. Proportion achieving target CSTI-500 steady-state Cmax with PK-guided dose individualization

    Proportion of participants whose observed CSTI-500 steady-state Cmax is within the protocol-defined target range for the assigned target concentration level, using plasma concentrations measured from scheduled PK sampling to guide dose adjustments.

    Time frame: 12 weeks

  3. Incidence of clinically significant findings in laboratory values

    Laboratory evaluations include hematology, blood chemistry, and urinalysis parameters.

    Time frame: 12 weeks

  4. Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)

    QT interval, corrected QT interval (QTc), PR interval, QRS duration, and heart rate will be measured by 12-lead electrocardiogram.

    Time frame: 12 weeks

  5. Incidence of clinically significant findings in vital signs

    Participants will be assessed for any clinically significant changes in vital parameters (systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and body temperature).

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) total score

    Change from baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) total score. The HQ-CT total score ranges from 0 to 36, with higher scores indicating greater hyperphagia.

    Time frame: 12 weeks

  2. Change from baseline in Aberrant Behavior Checklist - Community (ABC-C) total score and subscale scores

    Change from baseline in Aberrant Behavior Checklist - Community (ABC-C) total score and subscale scores. The ABC-C is a 58-item caregiver-reported questionnaire, with higher scores indicating more severe aberrant behavior.

    Time frame: 12 weeks

  3. Clinical Global Impression-Improvement (CGI-I) score

    Clinical Global Impression-Improvement (CGI-I) score assessed at Week 12. The CGI-I is a 7-point ordinal scale, with lower scores indicating greater improvement.

    Time frame: 12 weeks

  4. Change from baseline in Clinical Global Impression-Severity (CGI-S) score

    Change from baseline in Clinical Global Impression-Severity (CGI-S) score. The CGI-S is a 7-point ordinal scale, with lower scores indicating less severe illness (better outcome).

    Time frame: 12 weeks

  5. Change from baseline in Prader-Willi Syndrome Questionnaire (PADQ) score

    Change from baseline in the Prader-Willi Syndrome Questionnaire (PADQ) score. The PADQ is a caregiver-reported questionnaire, with higher scores indicating greater symptom severity (worse outcome).

    Time frame: 12 weeks

  6. Change from baseline in Caregiver Global Impression-Severity (careGI-S) score

    Change from baseline in Caregiver Global Impression-Severity (careGI-S) score. The careGI-S is a caregiver-reported ordinal scale, with lower scores indicating less severe symptoms (better outcome).

    Time frame: 12 weeks

  7. Caregiver Global Impression-Change (careGI-C) score

    Caregiver Global Impression-Change (careGI-C) score assessed at Week 12. The careGI-C is a caregiver-reported ordinal scale, with lower scores indicating greater improvement.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 16, 2026
StartActual
May 18, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07348601
Lead sponsor
ConSynance Therapeutics
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
May 18, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Beth Mack
Contact
bethmack@lbr-regulatory.com
859-426-5035

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion